Tuberculosis caused by the obligate intracellular pathogen, Mycobacterium tuberculosis, is one among the prime causes of death worldwide. An urgent remedy against tuberculosis is of paramount importance in the current scenario. However, the complex nature of this appalling disease contributes to the limitations of existing medications. The quest for better treatment approaches is driving the research in the field of host epigenomics forward in context with tuberculosis. The interplay between various host epigenetic factors and the pathogen is under investigation. A comprehensive understanding of how Mycobacterium tuberculosis orchestrates such epigenetic factors and favors its survival within the host is in increasing demand. The modifications beneficial to the pathogen are reversible and possess the potential to be better targets for various therapeutic approaches. The mechanisms, including histone modifications, DNA methylation, and miRNA modification, are being explored for their impact on pathogenesis. In this article, we are deciphering the role of mycobacterial epigenetic regulators on various strategies like cytokine expression, macrophage polarization, autophagy, and apoptosis, along with a glimpse of the potential of host-directed therapies.
Rv1899c, a previously identified HDAC1–ZBTB25-interacting protein of Mycobacterium tuberculosis, plays a crucial role in bacterial adaptation and immune modulation. Recombinant M. smegmatis-expressing Rv1899c (MS_ Rv1899c) showed enhanced survival under acidic and oxidative stress compared to vector controls, along with improved early intracellular growth in THP1-derived macrophages. This was accompanied by reduced reactive oxygen species (ROS), diminished cytokines associated with inflammation and downregulation of autophagy proteins ATG5, Beclin, and LC3, which ultimately skewed the immune response, suppressing the pro-inflammatory M1 macrophage population. Targeting Rv1899c with 3-aminobenzamide (3-AB) impaired intracellular bacterial survival and restored IL-12B expression, while its combination with the HDAC inhibitor C1994 significantly enhanced bacterial clearance. Structural modelling confirmed the high stereochemical quality of the Rv1899c macrodomain, and computational studies identified 3-AB as the strongest ligand (−5.75 kcal/mol), stabilized through hydrogen bonding and hydrophobic interactions with key residues. Molecular dynamics simulations conducted for 200 ns demonstrated stable protein–ligand interactions with consistent parameters, while MM/GBSA analysis indicated favourable binding energy (ΔG_bind = −6.6 kcal/mol), largely influenced by van der Waals and electrostatic forces. Together, these findings highlight Rv1899c as a mediator of stress resistance and immune evasion and propose it as a potential therapeutic target against M. tuberculosis.
Candida albicans is a deadly fungal pathogen, particularly in immunocompromised individuals, where a simple superficial infection rapidly transforms into life-threatening systemic candidiasis. Virulence factors of C. albicans include the yeast-to-hyphae transition, biofilm formation, and protease production, which are crucial for establishing infection. Targeting virulence factors is a promising strategy to combat C. albicans infections, which can overcome the limitations of conventional treatment modalities. Essential oils are important in this regard as they are used in traditional medicine due to their antimicrobial capabilities. This study is focused on the antivirulent activity of cumin essential oil (CEO), which significantly reduced the key virulence factors of C. albicans, such as germ tube formation and protease production. A subinhibitory concentration (0.015% v/v) of CEO downregulated the expression of the HWP1, ALS3, and RAS1 genes involved in regulating virulence. In silico studies demonstrated that major compounds of CEO interacted with key amino acid residues of secreted aspartyl proteases (Sap4, Sap5, Sap6) and heat shock protein (Hsp90), a regulator of hyphal formation. CEO significantly reduced biofilm formation of C. albicans in different simulated body fluids such as saliva, artificial urine, and tear fluid. Furthermore, CEO affected the host–pathogen interaction of C. albicans with THP-1 macrophages by increasing phagocytosis and inhibiting germ tube formation. Additionally, CEO treatment modulated the levels of pro-inflammatory and anti-inflammatory cytokines, suggesting that CEO also has immunomodulatory properties, in addition to its antivirulence activity. These results indicate that CEO could be a promising candidate for combating C. albicans infections.